Insider · CIK 0001470885

Booth Mark D

Reports to the SEC for 1 company · LA JOLLA, CA

sec.gov

Transactions

Companies

Filings

CIK

0001470885

Forms 4 and 5

Insider transactions

41 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2015-02-26	Orexigen Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+50K sh	$1.66	+$83K	53,810
2015-02-26	Orexigen Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−50K sh	$5.68	−$284K	3,810
2015-02-26	Orexigen Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−50K sh	—	—	563,924
2015-02-03	Orexigen Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+88.9K sh	—	—	88,925
2014-05-30	Orexigen Therapeutics, Inc.A Award	Chief Commercial Officer	AAward	+4,218 sh	$5.25	+$22.1K	8,028
2014-02-07	Orexigen Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+205K sh	—	—	205,000
2013-11-29	Orexigen Therapeutics, Inc.A Award	Chief Commercial Officer	AAward	+3,810 sh	$5.34	+$20.3K	3,810
2013-07-26	Orexigen Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+64.8K sh	$1.66	+$108K	64,767
2013-07-26	Orexigen Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−20K sh	$7.50	−$150K	29,045
2013-07-26	Orexigen Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−29K sh	$7.75	−$225K	0
2013-07-26	Orexigen Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−64.8K sh	—	—	613,924
2013-07-26	Orexigen Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−15.7K sh	$7.25	−$114K	49,045
2013-03-11	Orexigen Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−27.7K sh	$6.67	−$185K	0
2013-03-11	Orexigen Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+27.7K sh	$1.66	+$46K	27,685
2013-03-11	Orexigen Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−27.7K sh	—	—	678,691
2013-02-15	Orexigen Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+190K sh	—	—	190,000
2013-01-15	Orexigen Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+22.3K sh	$1.66	+$37K	22,315
2013-01-15	Orexigen Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−22.2K sh	$6.67	−$148K	100
2013-01-15	Orexigen Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−100 sh	$6.67	−$667.5	0
2013-01-15	Orexigen Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−22.3K sh	—	—	706,376
2012-06-28	Orexigen Therapeutics, Inc.Stock Option (right to buy)M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	−103K sh	—	—	728,691
2012-06-28	Orexigen Therapeutics, Inc.S Sale	Chief Commercial Officer	SSale	−103K sh	$5.66	−$585K	0
2012-06-28	Orexigen Therapeutics, Inc.M Exercise/Conversion	Chief Commercial Officer	MExercise/Conversion	+103K sh	$1.66	+$171K	103,309
2012-02-27	Orexigen Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+70K sh	—	—	70,000
2012-01-25	Orexigen Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+280K sh	—	—	280,000
2011-07-25	Orexigen Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	−832K sh	—	—	832,000
2011-07-22	Orexigen Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−80K sh	—	—	0
2011-07-22	Orexigen Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−107K sh	—	—	0
2011-07-22	Orexigen Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−45K sh	—	—	0
2011-07-22	Orexigen Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−150K sh	—	—	0
2011-07-22	Orexigen Therapeutics, Inc.Stock Option (right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−450K sh	—	—	0
2011-03-02	Orexigen Therapeutics, Inc.Employee Stock Option Grant (right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−107K sh	—	—	0
2011-03-02	Orexigen Therapeutics, Inc.Employee Stock Option Grant (right to buy)A Award	Chief Commercial Officer	AAward	+107K sh	—	—	107,000
2011-03-02	Orexigen Therapeutics, Inc.Employee Stock Option Grant (right to buy)A Award	Chief Commercial Officer	AAward	+45K sh	—	—	45,000
2011-03-02	Orexigen Therapeutics, Inc.Employee Stock Option Grant (right to buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−45K sh	—	—	0
2011-01-18	Orexigen Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+107K sh	—	—	107,000
2010-09-20	Orexigen Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+45K sh	—	—	45,000
2010-09-01	Orexigen Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+75K sh	—	—	75,000
2010-01-22	Orexigen Therapeutics, Inc.Stock option (right to buy)A Award	Chief Commercial Officer	AAward	+80K sh	—	—	80,000
2009-08-26	Orexigen Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+150K sh	—	—	150,000
2009-08-26	Orexigen Therapeutics, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+450K sh	—	—	450,000

Recent filings

Accepted (ET)
Mar 24
Orexigen Therapeutics, Inc.0001181431-15-003650
SEC(opens sec.gov)
Feb 54
Orexigen Therapeutics, Inc.0001181431-15-002033
SEC(opens sec.gov)
Feb 114
Orexigen Therapeutics, Inc.0001181431-14-006112
SEC(opens sec.gov)
Jul 294
Orexigen Therapeutics, Inc.0001181431-13-041739
SEC(opens sec.gov)
Mar 124
Booth Mark D0001181431-13-016465
SEC(opens sec.gov)
Feb 194
Booth Mark D0001181431-13-010707
SEC(opens sec.gov)
Jan 184
Booth Mark D0001181431-13-003836
SEC(opens sec.gov)

Companies

Orexigen Therapeutics, Inc.Chief Commercial Officer

Address

C/O OREXIGEN THERAPEUTICS, INC. 3344 N. TORREY PINES COURT, SUITE 200

LA JOLLA, CA, 92037